Celcuity Inc. (NASDAQ:CELC – Get Free Report) has earned an average recommendation of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $29.17.
Several equities analysts have commented on CELC shares. Lifesci Capital started coverage on Celcuity in a report on Monday, August 26th. They set an “outperform” rating and a $27.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $27.00 price target on shares of Celcuity in a report on Thursday, August 15th. Stifel Nicolaus raised their price objective on shares of Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday. Needham & Company LLC restated a “buy” rating and issued a $23.00 price objective on shares of Celcuity in a research note on Thursday, August 15th. Finally, Leerink Partners started coverage on Celcuity in a report on Monday, July 22nd. They set an “outperform” rating and a $29.00 price objective for the company.
Get Our Latest Stock Report on CELC
Institutional Trading of Celcuity
Celcuity Trading Down 0.1 %
Shares of CELC stock opened at $15.26 on Friday. Celcuity has a 12 month low of $8.39 and a 12 month high of $22.19. The company has a quick ratio of 14.95, a current ratio of 14.95 and a debt-to-equity ratio of 0.54. The business’s 50 day moving average is $15.78 and its two-hundred day moving average is $16.61. The company has a market cap of $535.64 million, a PE ratio of -5.49 and a beta of 0.75.
Celcuity (NASDAQ:CELC – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.09. During the same period last year, the company posted ($0.66) EPS. Equities analysts predict that Celcuity will post -2.54 EPS for the current year.
Celcuity Company Profile
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Featured Articles
- Five stocks we like better than Celcuity
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- How to Invest in Small Cap StocksÂ
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- Why is the Ex-Dividend Date Significant to Investors?
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.